Arnold, Douglas et al "Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (S6.002)." Neurology 90.15 Supplement (2018): S6.002. Web. 05 Oct. 2022.